Nuvation Bio Inc. NUVB
3.93 USD -0.06 (-1.50%)
As ofNov 16, 2026, 12:35 PM EST
3.85 Day range 4.00
3.85 52-week range 9.75
- YTD
- -56.14%
- 1 year
- -19.14%
News
gurufocus.com Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual
prnewswire.com Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting With nearly 40 months of follow-up, additional updated data from J201 study show the confirmed clinical benefit rate was 81.5% in patients with Grade 2 IDH1-mutant glioma Patients achieved a median…
defenseworld.net ACT Capital Partners L.P. Buys 579,500 Shares of Nuvation Bio Inc. $NUVB ACT Capital Partners L.P. bought a new position in Nuvation Bio Inc. (NYSE: NUVB) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 579,500…
prnewswire.com Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David…
seekingalpha.com Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients Nuvation Bio's Ibtrozi's roughly 50-month first-line durability means revenue depends on patients staying on therapy, not just new starts. Q3 Ibtrozi revenue rose 18% sequentially to $27.5 million,…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.benzinga.com RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17 RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.
benzinga.com Nuvation Bio Q3 2026 Earnings Call Transcript Nuvation Bio (NYSE:NUVB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.16) per share from the same period…
benzinga.com Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2…
benzinga.com Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519)…
